Surgery for high-risk localized prostate cancer

被引:11
|
作者
Schmitges, Jan [1 ]
Trinh, Quoc-Dien [2 ,3 ]
Walz, Jochen [4 ]
Graefen, Markus [5 ]
机构
[1] Univ Klinikum Hamburg Eppendorf, Martini Klin, Martinistr 52, D-20246 Hamburg, Germany
[2] Univ Montreal Hlth Ctr, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[3] Henry Ford Hlth Syst, Vattikutti Urol Inst, Detroit, MI USA
[4] Calmettes Canc Ctr, Inst Paoli, Dept Urol, Urol, Marseille, France
[5] Univ Klinikum Hamburg Eppendorf, Martini Klin, Urol, D-20246 Hamburg, Germany
关键词
high-risk prostate cancer; perioperative complications; prostatectomy; urinary incontinence;
D O I
10.1177/1756287211418722
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Treatment of men with high-risk prostate cancer (PCa) remains challenging for urologists. The complex natural history of high-risk PCa and the lack of specific and accurate definitions for high-risk disease impede treatment decision making. Historically, surgery in this patient group has been avoided based on the perception of ostensibly higher complication rates associated with inferior functional and oncological outcomes. To date, no randomized data comparing different therapy approaches have been made available. Several investigators have reported that continence rates in patients after radical prostatectomy (RP) for high-risk disease seem to be unaffected. Similarly, in a large proportion of these men, a nerve-sparing procedure can be performed without a significant negative impact on surgical margin rates and with comparable potency results. Moreover, extended pelvic lymph node dissection (EPLND) contributes to accurate pathological staging with a marginal effect on perioperative morbidity. With regards to the benefits of RP on local recurrence and cure rates, realistic expectations regarding the success of RP alone or in the context of a multimodal approach should be provided during patient counseling.
引用
收藏
页码:173 / 182
页数:10
相关论文
共 50 条
  • [1] Role of surgery in high-risk localized prostate cancer
    Lawrentschuk, N.
    Trottier, G.
    Kuk, C.
    Zlotta, A. R.
    [J]. CURRENT ONCOLOGY, 2010, 17 : S25 - S32
  • [2] Re: The Role of Surgery in High-risk Localized Prostate Cancer
    Van Poppel, Hendrik
    [J]. EUROPEAN UROLOGY, 2014, 66 (02) : 387 - 389
  • [3] High-risk localized prostate cancer: primary surgery and adjuvant therapy
    Skinner, EC
    Glode, LM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (03) : 219 - 227
  • [4] Chemotherapy for localized, high-risk prostate cancer
    Narayan, S
    Smith, DC
    Sandler, HM
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (02) : 152 - 157
  • [5] Management of High-Risk Localized Prostate Cancer
    Marciscano, Ariel E.
    Hardee, Matthew E.
    Sanfilippo, Nicholas
    [J]. ADVANCES IN UROLOGY, 2012, 2012
  • [6] Chemotherapy for high-risk localized prostate cancer
    Nakabayashi, M
    Oh, WK
    [J]. BJU INTERNATIONAL, 2006, 97 (04) : 679 - 683
  • [7] Surgery for high-risk prostate cancer
    Eden, Christopher
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (01) : 19 - 22
  • [8] Surgery for high-risk prostate cancer and metastatic prostate cancer
    Safir, Ilan J.
    Lian, Fei
    Alemozaffar, Mehrdad
    Master, Viraj A.
    [J]. CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 33 - 40
  • [9] Contemporary treatment of high-risk localized prostate cancer
    Tareen, Basir
    Kimmel, Joseph
    Huang, William C.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1069 - 1076
  • [10] Immunosuppressive milieu of high-risk localized prostate cancer
    Ricardo, Victor
    Febles, Adorno
    Adeegbe, Dennis
    Ahsan, Aarif
    Wu, Jiansheng
    Khodadad-Jamayran, Alireza
    Lepor, Herbert
    Wysock, James
    Taneja, Samir
    Huang, William C.
    Balar, Arjun Vasant
    Melamed, Jonathan
    Deng, Fang-Ming
    Ren, Qinghu
    Tsirigos, Aristotelis
    Kufe, Donald W.
    Heguy, Adriana
    Wong, Kwok-Kin
    Wise, David R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)